In otherwise healthy short children, quality of life and self-esteem are associated with coping skills and how supported they feel, not the degree of their short stature, according to a study recently published in The Journal of Pediatrics. Researchers led by Adda Grimberg, MD, a pediatric endocrinologist and Scientific Director of the Growth Center at Children’s...
Pediatric growth hormone deficiency treatments could soon be painless. Fernando Cassorla, MD, is traveling from Chile to Chicago to present research at ENDO 2023 that could potentially change the way pediatric hormone treatments are administered. If a pill could replace painful injections, patients and caregivers alike can finally wipe away their tears. A convenient, well...
The U.S. Food and Drug Administration (FDA) last month approved a new indication for somapacitan-beco injection 5 mg, 10 mg, or 15 mg for the treatment of children aged 2.5 years and older who have growth failure due to inadequate secretion of endogenous growth hormone. Novo Nordisk is marketing the treatment as Sogroya® The FDA approval...
Despite successful medical intervention, people with acromegaly don’t always share their clinician’s optimistic outlook. Eliza B. Geer, MD, director of Memorial Sloan Kettering’s Multidisciplinary Pituitary & Skull Base Tumor Center, takes us through a holistic approach to treating this often-confounding condition and how a team-based methodology is frequently the key to success. Recently, I was...
An excess of growth hormone in infancy leads to the rare yet confounding phenomenon of X-linked acrogigantism, which is known to be resistant to conventional pituitary tumor treatments in the pediatric population. However, new data suggests that pegvisomant could not only be a treatment option for these patients, but it could also improve quality-of-life measures....
Racial and gender disparities in healthcare begin early — including among children who could benefit from treatment for short stature. New research seems to show that white children — especially boys — are offered growth hormone stimulation tests at a significantly higher rate than girls or Black and Hispanic children. The racial, ethnic, and gender...
As the desire for a less frequently administered growth hormone treatment intensifies, clinicians are looking to researchers for the latest data on safety and efficacy. Luckily, as more studies are undertaken patients and clinicians may soon have a wealth of options. Since 1985, children with growth hormone deficiency (GHD) have been prescribed somatropin – recombinant...
ENDO 2022 saw the presentation of positive clinical data from the open-label extensions (OLEs) of two of the Phase 3 trials of oral octreotide for patients with acromegaly. Amryt is marketing the drug as Mycapssa. Data presented in a late-breaking poster presentation of the 2nd year of the OLE of OPTIMAL (NCT03252353), a randomized, double-blind...
Pediatric growth hormone deficiency treatments could soon be painless. Fernando Cassorla, MD, is traveling from Chile to Chicago to present research at ENDO 2023 that could potentially change the way pediatric hormone treatments are administered. If a pill could replace painful injections, patients and caregivers alike can finally wipe away their tears. A convenient, well...
Despite successful medical intervention, people with acromegaly don’t always share their clinician’s optimistic outlook. Eliza B. Geer, MD, director of Memorial Sloan Kettering’s Multidisciplinary Pituitary & Skull Base Tumor Center, takes us through a holistic approach to treating this often-confounding condition and how a team-based methodology is frequently the key to success. Recently, I was...
